SpringWorks Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
05 Dezembro 2023 - 2:32AM
SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage
biopharmaceutical company focused on severe rare diseases and
cancer, announced today the pricing of an underwritten public
offering of 9,482,758 shares of its common stock at a public
offering price of $29.00 per share. All of the shares in the
offering are being sold by SpringWorks. The gross proceeds from the
offering, before deducting underwriting discounts and commissions
and estimated offering expenses, are expected to be approximately
$275.0 million. The offering is expected to close on or about
December 7, 2023, subject to the satisfaction of customary closing
conditions. In addition, SpringWorks has granted the underwriters a
30-day option to purchase up to an additional 1,422,413 shares of
its common stock at the public offering price, less underwriting
discounts and commissions.
Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, Cowen
and Company, LLC and Guggenheim Securities, LLC are acting as joint
book-running managers for the offering.
An automatic shelf registration statement on Form S-3ASR
(including a prospectus) relating to these securities has been
filed with the Securities and Exchange Commission (SEC) and has
become effective.
The offering is being made only by means of a prospectus and
prospectus supplement that form part of the automatic shelf
registration statement. A preliminary prospectus supplement
describing the terms of the offering has been filed with the SEC
and forms a part of the effective registration statement. A copy of
the final prospectus supplement and accompanying prospectus
relating to the offering will be filed with the SEC and may be
obtained, when available, from: Goldman Sachs & Co. LLC,
Attention: Prospectus Department, 200 West Street, New York, NY
10282, or by telephone at (866) 471-2526 or by email at
prospectus-ny@ny.email.gs.com; J.P. Morgan Securities LLC,
Attention: Broadridge Financial Solutions, 1115 Long Island Avenue,
Edgewood, NY 11717, or by telephone at (866) 803-9204, or by email
at prospectus-eq_fi@jpmchase.com; Cowen and Company, LLC, 599
Lexington Avenue, New York, NY 10022, by email at
Prospectus_ECM@cowen.com or by telephone at (833) 297-2926; or
Guggenheim Securities, LLC, Attention: Equity Syndicate Department,
330 Madison Avenue, 8th Floor, New York, NY 10017, or by telephone
at (212) 518-9544, or by email at
GSEquityProspectusDelivery@guggenheimpartners.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About SpringWorks Therapeutics
SpringWorks is a commercial-stage biopharmaceutical company
applying a precision medicine approach to developing and delivering
life-changing medicines for people with severe rare diseases and
cancer.
Founded in 2017, SpringWorks has a diversified targeted oncology
pipeline spanning solid tumors and hematological cancers, including
clinical trials in rare tumor types and highly prevalent,
genetically defined cancers. OGSIVEO™, approved in the United
States for the treatment of adult patients with progressing desmoid
tumors who require systemic treatment, is SpringWorks’ first U.S.
Food and Drug Administration (FDA)-approved therapy. SpringWorks’
strategic approach and operational excellence in clinical
development have enabled it to rapidly advance its lead product
candidates into late-stage trials and enter into multiple
collaborations with innovators in industry and academia to unlock
the full potential for its portfolio and create more solutions for
patients with cancer.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including, without limitation, statements
regarding SpringWorks’ expectations with respect to the completion
and timing of the public offering. The words “may,” “will,”
“could,” “would,” “should,” “expect,” “plan,” “anticipate,”
“intend,” “believe,” “estimate,” “predict,” “project,” “potential,”
“continue,” “target” and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Any
forward-looking statements in this press release are based on
management’s current expectations and beliefs and are subject to a
number of risks, uncertainties and important factors that may cause
actual events or results to differ materially from those expressed
or implied by any forward-looking statements contained in this
press release, including, without limitation risks and
uncertainties associated with market conditions and the
satisfaction of customary closing conditions related to the
proposed offering, and other risks identified in the section
entitled “Risk Factors” in Item 1A of Part II of SpringWorks’
Quarterly Report on Form 10-Q for the quarter ended September 30,
2023, as well as discussions of potential risks, uncertainties and
other important factors in SpringWorks’ subsequent filings with the
SEC. SpringWorks cautions you not to place undue reliance on any
forward-looking statements, which speak only as of the date they
are made. SpringWorks disclaims any obligation to publicly update
or revise any such statements to reflect any change in expectations
or in events, conditions or circumstances on which any such
statements may be based, or that may affect the likelihood that
actual results will differ from those set forth in the
forward-looking statements. Any forward-looking statements
contained in this press release represent SpringWorks’ views only
as of the date hereof and should not be relied upon as representing
its views as of any subsequent date.
SpringWorks Contacts:
Kim DiamondVice President, Communications and Investor
RelationsPhone: 203-561-1646 Email: kdiamond@springworkstx.com
Samantha Hilson SandlerSenior Director, Investor RelationsPhone:
203-461-5501Email: samantha.sandler@springworkstx.com
SpringWorks Therapeutics (NASDAQ:SWTX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
SpringWorks Therapeutics (NASDAQ:SWTX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024